Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Oncology

The Biology of How HCC Develops

At a Glance

Hepatocellular carcinoma (HCC) typically develops over years due to chronic liver inflammation. This ongoing damage and repair cycle causes DNA mutations. The two main triggers for this process are viral infections like Hepatitis B or C, and metabolic conditions like fatty liver disease.

Return to Home

Understanding how Hepatocellular Carcinoma (HCC) develops is like looking at a fire: to put it out effectively, it helps to know what started it and what is fueling it. For most patients, HCC doesn’t happen suddenly; it is the result of years of “biological friction” that eventually causes healthy liver cells to transform into cancer [1][2].

The Core Mechanism: Chronic Injury

At its heart, HCC is a cancer driven by chronic inflammation [3][4]. When the liver is repeatedly injured—whether by a virus, fat buildup, or toxins—it enters a cycle of damage and repair [1]. This constant “emergency repair” mode leads to two critical problems:

  1. DNA Damage: Every time a cell divides to repair the liver, there is a small chance of a “typo” or mutation in its genetic code. Over years, these typos accumulate until the cell no longer follows the rules of normal growth [4][5].
  2. A Toxic Environment: Chronic injury creates a “microenvironment” full of inflammatory chemicals (like IL-6) and “reactive oxygen species” (unstable molecules that damage cells) [4][6]. This environment acts as a fertilizer for cancer cells, helping them grow and hide from your immune system [7][8].

The Two Main Paths to Cancer

While the end result is the same, the biological “startup” for HCC often follows one of two distinct paths: viral or metabolic.

1. The Viral Path (HBV and HCV)

Viral hepatitis, particularly Hepatitis B (HBV) and Hepatitis C (HCV), has long been the leading cause of HCC worldwide [9].

  • Direct Hijacking: In Hepatitis B, the virus can actually “sew” its own DNA into your liver cells’ DNA [10][11]. This insertional mutagenesis can directly turn on cancer-causing genes or break the “brakes” that normally stop tumors from forming [10][12].
  • Viral Proteins: The virus produces specific proteins (like HBx) that interfere with how your cells handle stress and repair their own DNA [13][14].

2. The Metabolic Path (MASLD/NASH)

A rapidly rising cause of HCC is Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD or “fatty liver disease” [11][15].

  • Lipotoxicity: When too much fat builds up in liver cells, it becomes “toxic.” This causes oxidative stress, a type of internal biological rust that damages the cell’s machinery [16][17].
  • Insulin Resistance: High levels of insulin and blood sugar can act as growth signals, accidentally telling pre-cancerous cells to multiply faster [15][18].
  • The “No-Scarring” Path: Importantly, research shows that metabolic HCC can sometimes develop before significant scarring (cirrhosis) occurs, unlike viral HCC which almost always requires advanced scarring first [19][20].

Why the Difference Matters

The biology of “how” your cancer started influences “how” it behaves today.

  • Genomic Stability: Viral HCC tends to have more “structural variations” or major breaks in the chromosomes [21].
  • Immune Response: The metabolic path creates a unique immunosuppressive environment [19]. For example, in metabolic liver disease, certain immune cells (like IgA+ cells) can actually “block” the warrior cells (CD8+ T-cells) that are supposed to kill cancer [7][22].
Feature Viral Path (HBV/HCV) Metabolic Path (MASLD/MASH)
Primary Trigger Viral DNA integration & proteins [10] Lipotoxicity & insulin resistance [15]
Inflammation Driven by immune system fighting virus [9] Driven by metabolic stress & fat [16]
Liver Scarring Almost always occurs in scarred liver [23] Can occur without advanced scarring [19]
Genomic Landscape High chromosomal instability [21] Epigenetic & metabolic reprogramming [24]

Regardless of the trigger, your medical team uses this biological understanding to choose the best strategy to “starve” the tumor and support your liver’s remaining healthy cells [25][26].

Common questions in this guide

How does hepatocellular carcinoma start?
HCC usually develops over years of chronic liver inflammation and injury. This constant cycle of damage and repair causes DNA mutations that eventually cause healthy liver cells to transform into cancer cells.
Can I get liver cancer without having cirrhosis?
Yes. While viral-induced liver cancer almost always requires advanced scarring or cirrhosis first, metabolic liver cancer from fatty liver disease can sometimes develop before significant liver scarring occurs.
Does the underlying cause of my liver cancer affect my treatment?
Yes, the biological start of your cancer influences how it behaves and interacts with your immune system. Knowing whether your HCC was triggered by a virus or metabolic factors helps your medical team choose the most effective medications or immunotherapies.
How does fatty liver disease lead to HCC?
When too much fat builds up in liver cells, it becomes toxic and causes oxidative stress, which damages the cells. This stress, along with insulin resistance, acts as a growth signal that can cause pre-cancerous cells to multiply rapidly.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Was my HCC likely triggered by a virus, metabolic factors like MASLD, or a combination of both?
  2. 2.Does the underlying cause of my cancer (viral vs. metabolic) change which medications or immunotherapies you would recommend?
  3. 3.Do I have significant liver scarring (cirrhosis), and how does that affect the risk of new tumors forming in the future?
  4. 4.What specific steps can I take to manage the "environment" of my liver (like blood sugar or viral load) to support my treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    The Nobel Prize in Physiology or Medicine-2020.

    Hagymási K

    Structural chemistry 2021; (32(2)):909-913 doi:10.1007/s11224-021-01731-z.

    PMID: 33584076
  2. 2

    Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.

    Galasso L, Cerrito L, Maccauro V, et al.

    International journal of molecular sciences 2024; (25(13)) doi:10.3390/ijms25137191.

    PMID: 39000296
  3. 3

    Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.

    Borgia M, Dal Bo M, Toffoli G

    Cancers 2021; (13(17)) doi:10.3390/cancers13174387.

    PMID: 34503196
  4. 4

    Oxidative stress and hepatocarcinogenesis.

    Fu Y, Chung FL

    Hepatoma research 2018; (4()) doi:10.20517/2394-5079.2018.29.

    PMID: 30761356
  5. 5

    Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.

    Wu H, Yang TY, Li Y, et al.

    Hepatology (Baltimore, Md.) 2020; (71(1)):148-163 doi:10.1002/hep.30801.

    PMID: 31155734
  6. 6

    Interleukin 6-dependent genomic instability heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis.

    Lanton T, Shriki A, Nechemia-Arbely Y, et al.

    Hepatology (Baltimore, Md.) 2017; (65(5)):1600-1611 doi:10.1002/hep.29004.

    PMID: 28027584
  7. 7

    Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

    Shalapour S, Lin XJ, Bastian IN, et al.

    Nature 2017; (551(7680)):340-345 doi:10.1038/nature24302.

    PMID: 29144460
  8. 8

    Interleukin-21 receptor signaling promotes metabolic dysfunction-associated steatohepatitis-driven hepatocellular carcinoma by inducing immunosuppressive IgA+ B cells.

    Xie Y, Huang Y, Li ZY, et al.

    Molecular cancer 2024; (23(1)):95 doi:10.1186/s12943-024-02001-2.

    PMID: 38720319
  9. 9

    Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

    Suresh D, Srinivas AN, Kumar DP

    Frontiers in oncology 2020; (10()):601710 doi:10.3389/fonc.2020.601710.

    PMID: 33330100
  10. 10

    Hepatitis B Viral Protein HBx: Roles in Viral Replication and Hepatocarcinogenesis.

    Li D, Hamadalnil Y, Tu T

    Viruses 2024; (16(9)) doi:10.3390/v16091361.

    PMID: 39339838
  11. 11

    Genetic variants underlying precancerous conditions of hepatocellular carcinoma.

    Guerrero JJG, Encarnacion PC, Del Rosario MAS, et al.

    International journal of cancer 2026; (158(3)):488-502 doi:10.1002/ijc.70092.

    PMID: 40833357
  12. 12

    A Pleiotropic Role of the Hepatitis B Virus Core Protein in Hepatocarcinogenesis.

    Lefeuvre C, Le Guillou-Guillemette H, Ducancelle A

    International journal of molecular sciences 2021; (22(24)) doi:10.3390/ijms222413651.

    PMID: 34948447
  13. 13

    Network pharmacology integrated with molecular docking and experimental validation elucidates the therapeutic potential of Forsythiae Fructus extract against hepatitis B virus-related hepatocellular carcinoma.

    Chen F, Cai Y, Chen C, Zhou J

    Frontiers in oncology 2025; (15()):1571537 doi:10.3389/fonc.2025.1571537.

    PMID: 40630198
  14. 14

    From bioinformatics to clinical translation: BIRC5 as a pivotal diagnostic biomarker and therapeutic target for NAFLD-driven HCC.

    Huang Y, He H, Xia X, et al.

    Cell biology and toxicology 2025; (42(1)):32 doi:10.1007/s10565-025-10128-1.

    PMID: 41372715
  15. 15

    New Insights into AMPK, as a Potential Therapeutic Target in Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatic Fibrosis.

    An H, Jang Y, Choi J, et al.

    Biomolecules & therapeutics 2025; (33(1)):18-38 doi:10.4062/biomolther.2024.188.

    PMID: 39702310
  16. 16

    Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.

    Takahashi Y, Dungubat E, Kusano H, Fukusato T

    Biomedicines 2023; (11(10)) doi:10.3390/biomedicines11102761.

    PMID: 37893134
  17. 17

    Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma.

    Lau HC, Zhang X, Yu J

    Nature reviews. Gastroenterology & hepatology 2025; (22(9)):619-638 doi:10.1038/s41575-025-01089-1.

    PMID: 40624229
  18. 18

    Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer.

    Karin M, Kim JY

    Pharmacological reviews 2025; (77(6)):100096 doi:10.1016/j.pharmr.2025.100096.

    PMID: 41197470
  19. 19

    The Emerging Challenge of Non-Cirrhotic MASLD-Related Hepatocellular Carcinoma: Etiology, Immunopathology, and Precision Oncology.

    Liu Y

    Liver cancer 2025; doi:10.1159/000550163.

    PMID: 41607858
  20. 20

    The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.

    Tobari M, Hashimoto E, Taniai M, et al.

    Journal of gastroenterology and hepatology 2020; (35(5)):862-869 doi:10.1111/jgh.14867.

    PMID: 31597206
  21. 21

    Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read Sequencing.

    Wei Z, Cao Y, Liu H, et al.

    MedComm 2026; (7(1)):e70570 doi:10.1002/mco2.70570.

    PMID: 41536518
  22. 22

    Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside.

    Yin Y, Feng W, Chen J, et al.

    Experimental hematology & oncology 2024; (13(1)):72 doi:10.1186/s40164-024-00539-x.

    PMID: 39085965
  23. 23

    The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer.

    Shiani A, Narayanan S, Pena L, Friedman M

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(3)):1073274817729240 doi:10.1177/1073274817729240.

    PMID: 28975833
  24. 24

    RNA splicing dysregulation in hepatocellular carcinoma: Molecular mechanisms, therapeutic targets, and intervention strategies-A comprehensive review.

    Xiong S, Hu L, Sun YY, et al.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026; (195()):119025 doi:10.1016/j.biopha.2026.119025.

    PMID: 41570787
  25. 25

    Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Benson AB, D'Angelica MI, Abbott DE, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

    PMID: 34030131
  26. 26

    Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

    Tilg H, Adolph TE, Dudek M, Knolle P

    Nature metabolism 2021; (3(12)):1596-1607 doi:10.1038/s42255-021-00501-9.

    PMID: 34931080

This page explains the biological development of hepatocellular carcinoma for educational purposes. It does not replace professional medical advice from your oncologist or hepatologist.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.